In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device/Diagnostics Quarterly Dealmaking Statistics, Q2 2018

A look at the financing, M&A and alliance activity in April-June 2018

Executive Summary

Second quarter device financing totaled $3.4 billion, less than half of the Q1 aggregate. Conversely, the $10.6 billion in device M&As was a 58% upsurge over the previous quarter. Like the device trends, total Q2 diagnostics financings (at $959 million) showed a 36% decline from Q1, while the $4.8 billion in M&A volume exhibited a significant increase over the previous quarter.

You may also be interested in...



FDA's Speedy Apple Watch De Novos Raise Questions For Industry

The recent US FDA de novo approvals for heart-rhythm analysis software on Apple's latest Apple Watch, which took about 30 days from submission to a decision that aligned with Apple's high-profile launch event, raised eyebrows in the medtech industry. Some in industry are concerned that the tech giant received preferential treatment over smaller companies, setting a bad precedent. But some say it could be a positive sign for the digital health industry at large.

Industry Is Falling Short In Digital Investments

Industry fundamentals to date suggest the device sector as a whole should be doing more to go all-in on digital and data analytics. That's the takeaway from EY's annual "Pulse of the Industry" report for the medtech space.

Bringing The Clinician's Rationale Into The Heart Of Strategic Decision-Making At Boston Scientific

Boston Scientific Corp. has been back on the M&A trail in a big way in 2018, with a succession of strategic additions of various sizes that all have potential patient and shareholder impact across – and beyond – its established divisions. Chief medical officer of 18 months Ian Meredith explains the thought processes driving this policy, and the added dimension a CMO can bring to the overall question of strategy.

Related Content

Topics

Related Deals

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel